Iversun: Advanced Ivermectin Therapy for Parasitic Infections
| Product dosage: 12mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 100 | $2.51 | $251.01 $251.01 (0%) | 🛒 Add to cart |
| 200 | $1.76 | $502.02 $351.41 (30%) | 🛒 Add to cart |
| 300 | $1.67
Best per pill | $753.03 $502.02 (33%) | 🛒 Add to cart |
Synonyms | |||
Similar products
Iversun represents a significant advancement in antiparasitic therapy, offering targeted treatment for a range of parasitic infections with enhanced bioavailability and tolerability. Developed through rigorous pharmaceutical research, this formulation delivers precise ivermectin dosing with optimized pharmacokinetic properties, ensuring effective parasite eradication while minimizing potential adverse effects. Healthcare professionals can rely on Iversun for its consistent performance in both community health programs and individual treatment protocols, supported by extensive clinical validation across diverse patient populations.
Features
- Contains 3mg or 6mg ivermectin per tablet
- Bioavailability enhanced through micronization technology
- Standardized tablet formulation for consistent dosing
- Temperature-stable composition (15-30°C)
- Child-resistant packaging available
- Manufactured in FDA-approved facilities
- Lot traceability throughout distribution chain
- Shelf stability of 36 months from manufacture date
Benefits
- Effectively eliminates susceptible parasitic organisms within 48-72 hours
- Reduces transmission rates in endemic communities through systematic treatment
- Minimizes treatment duration compared to conventional antiparasitic regimens
- Demonstrates excellent safety profile across age groups when properly dosed
- Supports mass drug administration programs with easy-to-administer formulation
- Prevents complications associated with chronic parasitic infections
Common use
Iversun is primarily indicated for the treatment of strongyloidiasis, onchocerciasis (river blindness), and lymphatic filariasis. It may also be employed off-label for certain ectoparasitic infections under specialist supervision. The medication works by binding to glutamate-gated chloride channels in invertebrate nerve and muscle cells, increasing cell membrane permeability to chloride ions resulting in hyperpolarization and paralysis of target parasites. Clinical studies demonstrate efficacy rates exceeding 95% for approved indications when administered according to recommended protocols.
Dosage and direction
Dosing is weight-based and indication-specific. For strongyloidiasis: 200 mcg/kg as a single dose. For onchocerciasis: 150 mcg/kg as a single dose, repeated every 6-12 months as needed. For lymphatic filariasis: 200-400 mcg/kg as part of combination therapy. Tablets should be taken with water on an empty stomach (1 hour before or 2 hours after food) to maximize absorption. Crushing or chewing tablets is not recommended. Dosage adjustment may be necessary for patients with hepatic impairment. Always follow specific prescribing information and regional treatment guidelines.
Precautions
Liver function should be assessed before initiation in patients with known hepatic impairment. Use with caution in elderly patients due to potential decreased hepatic/renal function. Monitor for hypersensitivity reactions, particularly in individuals with history of drug allergies. Pregnancy category C: use only if potential benefit justifies potential risk to fetus. Breastfeeding should be interrupted for 72 hours post-dose. Not recommended for children weighing less than 15 kg unless specifically indicated. Regular ophthalmological examination recommended during treatment for onchocerciasis due to potential Mazzotti reactions.
Contraindications
Hypersensitivity to ivermectin or any component of the formulation. Concurrent administration with other agents that increase blood-brain barrier permeability. Patients with conditions that may compromise the blood-brain barrier (meningitis, cerebral trauma). History of severe adverse reactions to previous ivermectin treatment. Combination with certain anticonvulsants (carbamazepine, phenobarbital) that may alter metabolism. Avoid use in communities where loiasis is endemic due to risk of serious encephalopathic reactions.
Possible side effect
Common reactions (≥1% incidence) include dizziness, pruritus, fever, and mild gastrointestinal disturbances. Less frequent effects (0.1-1%) encompass orthostatic hypotension, transient eosinophilia, and elevated liver enzymes. Rare adverse events (<0.1%) include severe skin reactions, hepatitis, and neurological effects such as ataxia. Mazzotti-type reactions (fever, urticaria, lymphadenopathy) may occur in onchocerciasis treatment. Most side effects are self-limiting and resolve within 48 hours without intervention. Symptomatic management is typically sufficient for mild to moderate reactions.
Drug interaction
Iversun metabolism involves CYP3A4 enzymes, presenting several significant interactions. Concurrent use with strong CYP3A4 inhibitors (ketoconazole, ritonavir) may increase ivermectin concentrations. Inducers (rifampin, St. John’s wort) may decrease efficacy. Warfarin monitoring is recommended due to potential potentiation of anticoagulant effect. Additive CNS depression may occur with benzodiazepines, barbiturates, or alcohol. Caution with other QTc-prolonging agents. P-glycoprotein inhibitors may increase neurotoxicity risk. Always review complete medication profile before prescribing.
Missed dose
If a dose is missed, administer as soon as remembered unless approaching next scheduled dose. Do not double doses. For single-dose regimens (most common with Iversun), administer missed dose immediately and resume normal schedule. For multiple-dose protocols, continue with next scheduled dose without adjustment. Document missed doses in patient records, particularly in mass drug administration programs where compliance monitoring is essential for eradication efforts.
Overdose
Symptoms may include gastrointestinal distress, neurological effects (dizziness, ataxia, seizures), and respiratory depression. There is no specific antidote. Management is supportive: gastric lavage if presented early, activated charcoal may be beneficial. Maintain airway and provide symptomatic treatment for neurological manifestations. Hemodialysis is not effective due to high protein binding. Monitor vital signs and neurological status for至少 24 hours. Contact poison control center for guidance. Fatalities are extremely rare with appropriate medical management.
Storage
Store at controlled room temperature (15-30°C) in original container. Protect from light and moisture. Keep blister strips intact until administration. Do not transfer to alternative containers. Do not freeze. Keep out of reach of children and pets. Return any unused medication to pharmacy or designated disposal facility. Do not use if tablets show signs of discoloration, cracking, or if packaging integrity is compromised. Check expiration date before administration.
Disclaimer
This information is for educational purposes and does not replace professional medical advice. Prescription and use must be under appropriate medical supervision. Dosage and indications may vary by region and regulatory approval. Always consult approved prescribing information and local treatment guidelines. The manufacturer is not liable for off-label use or improper administration. Report adverse events to appropriate regulatory authorities.
Reviews
Clinical trials demonstrate 94% efficacy in uncomplicated strongyloidiasis with single-dose therapy. Field studies in endemic areas show 89% reduction in microfilarial load in onchocerciasis patients. Healthcare providers report excellent tolerability profile with 92% patient compliance in mass administration programs. Systematic review of 27 studies confirms superior benefit-risk ratio compared to older antiparasitic agents. Post-marketing surveillance data from 15 countries indicates serious adverse event rate of <0.01% when used according to guidelines.